BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

University of Zagreb researcher Beata Halassy treated her breast cancer with an unproven virus-based therapy using viruses ...

A groundbreaking treatment has been announced for women with an extremely aggressive form of breast cancer. Siteman Cancer ...

BioNTech, the German developer of a widely used mRNA vaccine for the coronavirus, agreed to pay US$800 million (HK$6.24 ...

Over the summer, BioNTech released Phase 2 data on its mRNA cancer vaccine in the works alongside Regeneron. The vaccine, ...

BioNTech SE (BNTX) has released an update. BioNTech SE is set to acquire Biotheus in a deal valued at $800 million, aiming to strengthen its ...

On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...

The acquisition was part of BioNTech's broader oncology strategy, backed by the financial success of its Covid-19 vaccine ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

Germany pharmaceutical company BioNTech, which shot to global prominence after its early coronavirus vaccine, has boosted its ...

BioNTech (BNTX) plans to initiate multiple registration trials in 2024 and 2025 that will evaluate BNT327/PM8002 in combination with chemotherapy for the treatment of small cell lung cancer, non-small ...